ERBB2 and neoplasm: Several molecules have been identified as potential tumor antigens for CAR T cell therapy targeting primary brain tumors through immunohistochemical (IHC) analysis including EGFR/EGFRvIII, IL13Rα2, HER2 and B7-H3 (14).